



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07K 15/00, C12N 1/19 C12P 21/02, C12N 15/62</p>	<p>A1</p>	<p>(11) International Publication Number: WO 92/05198 (43) International Publication Date: 2 April 1992 (02.04.92)</p>
<p>(21) International Application Number: PCT/US91/06489 (22) International Filing Date: 13 September 1991 (13.09.91) (30) Priority data: 582,636 14 September 1990 (14.09.90) US (60) Parent Application or Grant (63) Related by Continuation US 582,636 (CIP) Filed on 14 September 1990 (14.09.90) (71) Applicant (for all designated States except US): CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): TEKAMP-OLSON, Patricia [US/US]; 80 Camino de Herrera, San Anselmo, CA 94960 (US). GALLEGOS, Carol, Ann [US/US]; 605 Carmel Avenue, Albany, CA 94706 (US).</p>	<p>(74) Agents: KAGAN, Sarah, A. et al.; Banner, Birch, McKie & Beckett, 1001 G Street, N.W., 11th Floor, Washington, DC 20001 (US). (81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US. Published With international search report.</p>	

(54) Title: EXPRESSION OF MACROPHAGE INDUCIBLE PROTEINS (MIPs) IN YEAST CELLS

AMINO ACID ALIGNMENT OF MIP-1 HOMOLOGS

1. hu-MIP-1 α	1	HqVSTaALAVLLCTMaLCNQ FSAa1aADTPtACCFsYtSRqIPqnFiaDYFETSSqCSkPGVIFLTKR ₈₀
2. mu-MIP-1 α	1	MKVSTcALAVLLCTMELCNQvFSAPyGADTPtACCFsY SRkIPRqFivDYFETSSLCsqPGVIFLTKR ₈₀
3. mu-MIP-1 β	1	MKLCV ₈₁ aLSLLLVAAPCaPqFSAPMGSDPPTaCCFSYTSRqLhR ₈₂ FVmDYETSSLCskPAVVFLTKR ₈₀
4. hu-MIP-1 β	1	MKLCVt ₈₁ vLSLl ₈₂ LVAAAPCaPa1SAPMGSDPPTaCCFSYTaRkLpRnFVvDYETSSLCsqPAVVf ₈₃ qTKR ₈₀
1. hu-MIP-1 α	72	vCADpsEeWVQRYvsDLELa
2. mu-MIP-1 α	72	ICADskEtWVQYIcDLELNA
3. mu-MIP-1 β	73	ICAnPSEpWvtEYmsDLELm
4. hu-MIP-1 β	73	vCApSEaWVqEYvyDLELm

(57) Abstract

Methods for the expression of mammalian MIP-1 α and MIP-1 β are disclosed. The methods generally comprise introducing into a yeast cell, a DNA molecule capable of directing the expression and if desired the secretion of either MIP-1 α or MIP-1 β . Methods for expression of constructs encoding both MIP-1 α and MIP-1 β are also described. The MIP molecules so produced are biologically active.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE ⁺	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

EXPRESSION OF MACROPHAGE INDUCIBLE
PROTEINS (MIPs) IN YEAST CELLS

BACKGROUND OF THE INVENTION

Macrophage inducible proteins (MIPs) are proteins that are produced by certain mammalian cells (for example, macrophages and lymphocytes) in response to stimuli such as gram negative bacterial lipopolysaccharide and concanavalin A. Thus, the MIP molecules may have diagnostic and therapeutic utility for detecting and treating infections, cancer, myelopietic dysfunction and auto-immune diseases.

Murine MIP-1 is a major secreted protein from lipopolysaccharide (LPS)-stimulated RAW 264.7 cells, a murine macrophage tumor cell line. It has been purified and found to consist of two related proteins MIP-1 α and MIP-1 β (Wolpe et al., 1987 J. Exp. Med. 167: 570; Sherry et al., 1988, J. Exp. Med. 168: 2251).

The cDNAs for both murine MIP-1 α and murine MIP-1 β have been cloned and sequenced (Davatellis et al., 1988, J. Exp. Med. 167:1939; Sherry et al., op. cit.) The cloning and sequencing of cDNAs corresponding to murine MIP-1 α and MIP-1 β have also been accomplished (Brown et al., 1989, J. Immun. 142:679; Kwon and Weissman, 1989, Proc. Natl. Acad. Sci. USA 86:1963 and by Brown al., op. cit.) Both groups isolated these homologs of MIP-1 α and/or MIP-1 β from cDNA libraries prepared from RNA of murine helper T-cells that had been activated by treatment with concanavalin A. These results suggest that MIP-1 α and MIP-1 β may play a role in T-cell activation.

Several groups have cloned what are likely to be the human homologs of MIP-1 α and MIP-1 β . In all cases, cDNAs were isolated from libraries prepared against activated T-cell RNA. Thus both Obaru et al., (J. Biochem. 99:885, 1986) and Zipfel et al. (J. Immun. 142:1582, 1989) have reported the cloning of a cDNA that encodes a protein with high homology to MIP-1 α (76%). Similarly, Brown et al, op cit., Zipfel

et al., op. cit.; Lipes et al., (Proc. Natl. Acad. USA 85:9704, 1988) and Miller, et al. (J. Immun., 143:2907, 1989) have reported the cloning and sequencing of human cDNAs, which predict a protein with high homology to MIP-1 β (75%). In addition to the above described highly homologous proteins, MIP-1 α and MIP-1 β belong to a newly described family of related proteins which have immunomodulatory activities (see Sherry et al., op. cit. for a review).

The definition of the bioactivities of MIP-1 has begun and has utilized native MIP-1 and very recently recombinant MIP-1 α and MIP-1 β . Purified native MIP-1 (comprising MIP-1 α and MIP-1 β polypeptides) causes acute inflammation when injected either subcutaneously into the footpads of mice or intracisternally into the cerebrospinal fluid of rabbits (Wolpe and Cerami, 1989, FASEB J. 3:2565; Saukkonen, et al., 1990, J. Exp. Med., 171:439). Native MIP-1 evokes a monophasic fever of rapid onset in rabbits when injected intravenously (Davatelis, et al., 1989, Science, 243:1066). In addition to these pro-inflammatory properties of MIP-1, which may be direct or indirect, MIP-1 has been recovered during the early inflammatory phase of wound healing in an experimental mouse model employing sterile wound chambers (Fahey, et al., 1990, Cytokine, 2:92).

MIP-1 may also participate in immune regulation. Antigen and nitrogen stimulation of quiescent T cells markedly induces the expression of several members of this cytokine superfamily including MIP-1 α , MIP-1 β , MIP-2 and IL-8 (Sherry and Cerami, 1991, Curr. Opin. Immun., 3:56). MIP-1 has several effects on macrophage function. Although not directly cytotoxic for WEH1 tumor cells, MIP-1-treated macrophages exhibited enhanced antibody-independent macrophage cytotoxic for tumor targets. MIP-1 treatment stimulated proliferation of mature tissue macrophages; this effect was synergistic with both CSF-1 and GM-CSF. Thioglycollate-elicited peritoneal exudate macrophages incubated with native doublet MIP-1 expressed TNF and IL-1 β mRNA, and these inductive effects were enhanced significantly when the cells were co-stimulated with IFN- γ . Purified preparations of the recombinantly-derived MIP-1 α peptide alone induced TNF and IL-6 in macrophages, but MIP-1 β did not. In fact, as little as two-fold

excess MIP-1 β blocked TNF-induction by MIP-1 α to a significant degree. By contrast to these apparent "macrophage activating" properties of MIP-1, the cytokine failed to trigger the macrophage oxidative burst, or to upregulate the expression of Ia on the macrophage surface. Taken together, these data reveal that MIP-1 peptides act as autocrine modulators of their cells of origin, and raise the possibility that MIP-1 peptides may play a role in modulating macrophage responses to inflammatory stimuli *in vivo*.

Among the bioactivities defined for native MIP-1 and recombinant MIP-1 α , and MIP-1 β are colony stimulating factor promoting activity. (Broxmeyer, et al., J. Exp. Med. 170:1583, 1989; Broxmeyer, et al., Blood 76:1110, 1990). Native murine MIP-1 or recombinant murine MIP-1 α but not recombinant MIP-1 β have also been found to inhibit the proliferation of less differentiated erythropoietin IL-3 dependent hematopoietic progenitor cells. (Graham, et al., Nature 344:442, 1990, Broxmeyer, et al., Blood, 76:1110, 1990.) Due to the necessity for quantities of purified factors to pursue definition of bioactivities, and the difficulty of isolating these factors from natural sources, it is desirable to produce MIP proteins by recombinant DNA technology.

MIP-1 and some members of the MIP-1 related gene family have been expressed by recombinant DNA technology as described below. Included as well is background data on members of the MIP-2 gene family, the members of which are distantly related to members of the MIP-1 gene family. Murine MIP-1 α and MIP-1 β have been independently expressed in COS cells (Graham, et al., op. cit.) LD78 cDNA (Obaru, et al., op. cit.) which encodes a protein that is likely to be the human homolog of murine MIP-1 α has been expressed in *E. coli* as a carboxyl terminal fusion to human IL-2 as well as in COS cells (Yamamura, et al., J. Clin. Invest. 84:1707, 1989). Human I-309, a cDNA that encodes a protein with homology to the MIP-1 family of proteins, has been expressed in COS-1 cells in order to confirm that it encodes a secreted protein (Miller, et al., op. cit.). JE, a cDNA that encodes a protein with homology to MIP-1 α and MIP-1 β , has been expressed in COS-1 cells; it encodes a polypeptide core of about 12 kDa (Rollins, et al., 1988, Proc. Natl. Acad. Sci. USA 85:3738).

KC, a cDNA that encodes a protein with homology to MIP-2, has been expressed in COS-1 cells to show that it encodes a secreted protein (Oguendo et al., 1989, J. Biol. Chem. 264:4133) Connective tissue activating peptide-III (CTAP, Mullenbach et al., 1986, J. Biol. Chem. 261:719) and IP-10, (Luster and Ravetch, 1987, J. Exp. Med. 166:1084) both members of the MIP-2 gene family, have been expressed as an α -factor fusion in yeast and in E. coli, respectively. Maione et al., (1990, Science 247:77) expressed human platelet factor 4, (MIP-2 family) in E. coli as a protein fusion to 35 amino acids of E. coli β -glucuronidase. The insoluble fusion must be cleaved with cyanogen bromide in order to generate bioactive material. Lindley et al., (1988, Proc. Natl. Acad. Sci. USA, 85:9199) have expressed NAF (IL-8), a member of the MIP-2 family, in E. coli. After purification and renaturation, this recombinant protein was found to have the same bioactivity identified for the native molecule. Furuta et al., (1989, J. Biochem. 106:436) have also expressed IL-8 (MDNCF) in E. coli. Lipes, et al. (op. cit.) described baculovirus expression of Act-2 cDNA, which encodes human MIP-1 β . Finally, Gimbrone et al., (1989 Science 246:1601) have expressed endothelial IL-8 in human 293 cells and have shown that the recombinant and natural material have the same bioactivity. However, MIP-1 α and MIP-1 β have yet to be expressed in yeast cells.

Thus, there is a need in the art for additional sources of mammalian inflammation mediator proteins to provide an economical way to obtain useful amounts of the proteins.

SUMMARY OF THE INVENTION

It is an object of the invention to provide a DNA molecule which is active as a template for producing mammalian macrophage inflammatory proteins (MIPs) in yeast.

It is another object of the invention to provide a yeast cell containing a DNA molecule which is active as a template for producing mammalian macrophage inflammatory proteins.

It is yet another object of the invention to provide a method of producing MIP-1 polypeptides.

It is still another object of the invention to provide MIP-1 compositions.

These and other objects of the invention are provided by one or more of the embodiments described below. In one embodiment, a DNA molecule is provided which comprises, in order of transcription: (a) a transcription regulatory region operative in a yeast; (b) a region which encodes a mammalian protein selected from the group consisting of MIP-1 α , and MIP-1 β ; said molecule active as a template for producing the mammalian protein in yeast.

In another embodiment of the invention a yeast cell is provided which contains a DNA molecule comprising, in order of transcription: (a) a transcription regulatory region operative in a yeast; (b) a region which encodes a mammalian protein selected from the group consisting of MIP-1 α , and MIP-1 β ; said molecule active as a template for producing the mammalian protein in yeast.

In still another embodiment of the invention a method is provided for producing a MIP polypeptide which comprises: growing a yeast cell in a nutrient medium whereby a MIP is expressed, said cell having a DNA molecule comprising in order of transcription: (a) a transcription regulatory region operative in a yeast; (b) a region which encodes a mammalian protein selected from the group consisting of MIP-1 α , and MIP-1 β ; said molecule active as a template for producing the mammalian protein in yeast.

In still another embodiment of the invention a composition is provided which comprises a mammalian protein selected from the group consisting of murine MIP-1 α , murine MIP-1 β , human MIP-1 α and human MIP-1 β , wherein the MIP is substantially free of non-MIP, mammalian proteins, and wherein the MIP is synthesized in a yeast cell.

The present invention thus provides the art with economical means to produce mammalian MIP proteins in ample quantities. This allows the full range of their bioactivities to be determined, and allows their use diagnostically and therapeutically.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 displays the cDNA sequence and predicted protein sequence of human MIP-1 α .

Figure 2 displays the cDNA sequence and predicted protein sequence of human MIP-1 β .

Figure 3 shows an alignment of the predicted amino acid sequences of MIP-1 homologs.

DETAILED DESCRIPTION OF THE INVENTION

It is a finding of the present invention that the mammalian MIP proteins can be expressed in and secreted from yeast cells. The proteins so expressed have biological activity. Thus yeast cells transformed with appropriate DNA constructs are suitable sources of MIP for therapeutic and investigational purposes.

MIP-1 is a monokine which acts as a primary negative regulator of hematopoietic stem cell proliferation. For example, MIP-1 is known to inhibit DNA synthesis in primitive hematopoietic cells (CFU-A) (Graham, et al., op. cit.). In addition, it enhances proliferation of more mature hematopoietic cells, including CFU-GM (Broxmeyer, et al., op. cit.) which have been stimulated with GM-CSF.

According to the findings of the present invention DNA molecules and host cells are provided for making MIP-1 proteins in yeast. The DNA molecules contain a region which encodes at least one mammalian MIP-1 protein. The MIP-1 may be human or murine, for example, and may consist of either the α or the β subunit. The MIP-1 coding region may also encode related proteins such as "muteins." These are closely related proteins which have been altered slightly to change one or more amino acids of the sequence, for example by substitution, deletion or insertion. Preferably less than about 8 amino acids have been altered, usually 4 or less, and more typically 2 or less. It may be preferred to make conservative substitutions, i.e., exchanging one amino acid for another of similar properties, such as charge. Muteins typically retain all of the activity of the parent protein, but may have increased stability or other useful properties relative to the natural protein. The MIP-1 coding region may also

encode a truncated MIP-1. Typically the truncated protein retains activity or unique epitopes of MIP-1.

The coding region is linked to a transcription regulatory region which is operative in a yeast. The transcription regulatory region may provide inducible or constitutive expression, as is desired. At a minimum, the regulatory region provides a promoter for initiation of transcription by RNA polymerase. The regulatory region may be derived from any yeast gene having the desired regulatory properties. For example, the yeast alcohol dehydrogenase, hexokinase, enolase, glyceraldehyde-3-phosphate dehydrogenase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase promoters can be used. These promoters are well known in the art. The transcription regulatory region is linked to the coding region such that transcription from the regulatory region continues through the coding region. When the DNA molecule of the invention is present in a yeast cell, MIP messenger RNA is made and translated. Expression according to the present invention denotes transcription and translation of a DNA sequence to produce a MIP protein.

A yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g., structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically includes an RNA polymerase binding site (the "TATA Box") and a transcription initiation site. A yeast promoter may also have a second domain called an upstream activator sequence (UAS), which, if present, is usually distal to the structural gene. The UAS permits regulated (inducible) expression. Constitutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby either enhancing or reducing transcription.

Yeast is a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic

pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase (ADH) (E.P.O. Pub. No. 284044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (E.P.O. Pub. No. 329203). The yeast PHO5 gene, encoding acid phosphatase, also provides useful promoter sequences [Miyahara, et al., (1983) Proc. Natl. Acad. Sci. USA 80:1].

In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For example, UAS sequences of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. Examples of such hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region (U.S. Patent Nos. 4,876,197; 4,880,734). Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the ADH2, GAL4, GAL10, or PHO5 genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or PyK (E.P.O. Pub. No. 164556). Furthermore, a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. See, e.g., Cohen, et al. (1980) Proc. Natl. Acad. Sci. USA 77:1078; Henikoff, et al. (1981) Nature, 283:835; Hollenberg, et al., (1981) Curr. Topics Microbiol. Immunol. 96:119, Hollenberg, et al., "The Expression of Bacterial Antibiotic Resistance Genes in the Yeast Saccharomyces cerevisiae," in: Plasmids of Medical, Environmental and Commercial Importance (eds. K.N. Timmis and A. Puhler); Mercereau-Puigalon, et al. (1980) Gene 11:163; Panthier, et al. (1980) Curr. Genet., 2:109.

A promoter sequence may be directly linked with the DNA molecule encoding MIP, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide.

Fusion proteins provide an alternative to direct expression. Typically, a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the yeast or human superoxide dismutase (SOD) gene, can be linked at the 5' terminus of a foreign gene and expressed in yeast. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See, e.g., EPO Pub. No. 196056. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin "leader" or "pro-" region that preferably retains a site for a processing enzyme (e.g. ubiquitin-specific processing protease) to cleave the ubiquitin from the foreign protein. Through this method, therefore, native foreign protein can be isolated (PCT WO 88/024066; commonly owned U.S. Patent Application Serial No. 390,599, filed 7 August 1989, the disclosure of which is incorporated herein by reference).

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provide for secretion in yeast and the foreign gene. Preferably, there are processing sites (in vivo or in vitro) encoded between the leader fragment and the foreign gene. Preferred in vivo sites include dibasic sequences such as lys-lys, arg-arg, lys-arg, and arg-lys. The leader sequence fragment typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the yeast invertase gene (E.P.O. Pub. No. 12,873; J.P.O. Pub. No. 62,096,086) and the A-factor gene (U.S. Patent No. 4,588,684). Alternatively, leaders of non-yeast origin, such as an interferon leader, exist that also provide for secretion in yeast (U.S. Patent No. 4,775,622). Concomitant cleavage of the signal peptide from the MIP is also desirable. This is usually accomplished at a processing site. The processing is preferably accomplished in vivo by endogenous yeast enzymes during the process

of translocation. Alternatively, in vitro processing can be employed using non-yeast enzymes or chemical cleavage.

A preferred class of secretion leaders are those that employ a fragment of the yeast alpha-factor gene, which contains both a "pre" signal sequence, and a "pro" region. The types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated alpha-factor leaders (typically about 25 to about 50 amino acid residues) (U.S. Patent Nos. 4,546,082 and 4,870,008; E.P.O. Pub. No. 324274). Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast, but a pro-region from a second yeast alpha-factor. (See, e.g., PCT WO 89/02463.)

The DNA molecules of the present invention will typically contain termination signals for transcription at the 3' end of the MIP protein coding region. This signal can be from any yeast gene, such as those used to supply promoters or signal sequences. In addition, the DNA molecules will typically contain a replication origin so that the DNA molecule can function as an autonomous unit for DNA replication. Often the DNA molecule will be in the form of a plasmid, although cosmids, viruses and mini-chromosomes can also be used. Often, the DNA molecule will be bifunctional, i.e., able to maintain itself in cells of two different genera.

Examples of yeast-bacteria shuttle vectors include YEp24 [Botstein, et al., (1979) Gene, 8:17-24], pCl/1 [Brake, et al., (1984) Proc. Natl. Acad. Sci. USA, 81:4642-4646], and YRp17 [Stinchcomb, et al., (1982) J. Mol. Biol., 158:157]. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and typically about 10 to about 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host. See, e.g., Brake, et al., supra.

Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors typically contain at least one sequence homologous to a yeast chromosome that allows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromosome [Orr-Weaver, et al. (1983), Methods in Enzymol., 101:228-245]. An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. See Orr-Weaver, et al., supra. One or more expression constructs may integrate, possibly affecting levels of recombinant protein produced [Rine, et al., (1983) Proc. Natl. Acad. Sci., USA 80:6750]. The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression construct.

Typically, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed. Selectable markers may include biosynthetic genes such as ADE2, HIS4, LEU2, TRP1, and URA3. Selectable markers may also include drug resistance genes such as ALG7 or a G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic substances, such as certain metals. For example, the presence of CUP1 allows yeast to grow in the presence of copper ions [Butt et al. (1987) Microbiol. Rev. 51:351].

Expression vectors, either extrachromosomal replicons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors have been developed for inter alia, the following yeasts: Candida albicans [Kurtz, et al. (1986) Mol. Cell. Biol., 6:142], Candida maltosa [Kunze, et al. (1985), J. Basic Microbiol., 25:141], Hansenula polymorpha [Gleeson, et al., (1986) J.

Gen. Microbiol., 132:3459; Roggenkamp, et al. (1986), Mol. Gen. Genet., 202:302], Kluyveromyces fragilis [Das, et al., (1984), J. Bacteriol., 158:1165], Kluyveromyces lactis [De Louvencourt et al., (1983), J. Bacteriol., 154:737; Van den Berg, et al., (1990) Bio/Technology, 8:135], Pichia guillermondii [Kunze et al., (1985), J. Basic Microbiol., 25:141], Pichia pastoris [Cregg, et al., (1985), Mol. Cell Biol., 5:3376; U.S. Patent Nos. 4,837,148, 4,879,231, and 4,929,555], Saccharomyces cerevisiae [Hinnen et al., (1978), Proc. Natl. Acad. Sci. USA, 75:1929; Ito, et al., (1983) J. Bacteriol., 153:163], Schizosaccharomyces pombe [Beach and Nurse (1981), Nature, 300:706], and Yarrowia lipolytica [Davidow, et al., (1985), Curr. Genet., 10:39-48; Gaillardin, et al. (1985), Curr. Genet., 10:49].

In general, DNA encoding a mammalian MIP may be obtained from human, murine, or other sources by constructing a cDNA library from mRNA isolated from mammalian tissue, and screening with labeled DNA probes encoding portions of the human or murine chains in order to detect clones in the cDNA library that contain homologous sequences. Alternatively, polymerase chain reaction (PCR) amplification of the cDNA (from mRNA) and subcloning and screening with labeled DNA probes may be used. Clones may be analyzed by restriction enzyme analysis and nucleic acid sequencing so as to identify full-length clones. If full-length clones are not present in the library, fragments can be recovered from the various clones and ligated at restriction sites common to the clones to assemble a clone encoding a full-length molecule. Any sequences missing from the 5' end of the cDNA may be obtained by the 3' extension of synthetic oligonucleotides complementary to MIP sequences using mRNA as a template (the primer extension technique.) Alternatively, homologous sequences may be supplied from known cDNAs derived from human or murine sequences disclosed herein.

The practice of the present invention will employ unless otherwise indicated, conventional molecular biological, microbiological and recombinant DNA techniques, all within the skill of the ordinary artisan. Such techniques are set forth in the literature. See, e.g., Maniatis, Fritsch & Sambrook, "Molecular Cloning: A Laboratory

Manual" (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" (B.D. Hames & S.J. Higgins eds. 1985); "Transcription and Translation" (B.D. Hames & S.J. Higgins eds. 1984); "Animal Cell Culture" (R.I. Freshney ed. 1986); "Immobilized Cells and Enzymes: (IRL Press, 1986); B. Perbal, "A Practical Guide to Molecular Cloning" (1984).

As used herein, "yeast" includes ascosporegenous yeasts (Endomycetales), basidiosporegenous yeasts and yeast belonging to the Fungi imperfecti (Blastomycetes). The ascosporegenous yeasts are divided into two families. Spermophthoraceae and Saccharomycetales. The latter is comprised of four subfamilies, Schizosaccharomycoidae (e.g., genus Schizosaccharomyces), Nadsonioideae, Lipomycoideae and Saccharomycoidae (e.g., genera Pichia, Kluyveromyces and Saccharomyces). The basidiosporegenous yeasts include the genera Leucosporidium, Rhodosporidium, Sporidiobolus, Filobasidium and Filobasidiella. Yeast belonging to the Fungi Imperfecti are divided into two families, Sporobolomycetaceae (e.g., genera Sporobolomyces, Bullera) and Cryptococcaceae (e.g., genus Candida). Of particular interest to the present invention are species within the genera Pichia, Kluyveromyces, Saccharomyces, Schizosaccharomyces and Candida. Of particular interest are the Saccharomyces species S. cerevisiae, S. carlsbergensis, S. diastaticus, S. douglasii, S. kluyveri, S. norbensis and S. oviformis. Species of particular interest in the genus Kluyveromyces include K. lactis. Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in Biology and Activities of Yeast (F.A. Skinner, S.M. Passmore & R. Davenport eds. 1980) (Soc. App. Bacterial. Symp. Series No. 9). In addition to the foregoing, those of ordinary skill in the art are presumably familiar with the biology of yeast and the manipulation of yeast genetics. See, e.g., Biochemistry and Genetics of Yeast (M. Bacila, B.L. Horecker & A.O.M. Stoppani eds. 1978); The Yeasts (A.H. Rose & J.S. Harrison eds., 2nd ed., 1987); The Molecular Biology of the Yeast Saccharomyces (Strathern et al., eds. 1981). The disclosures of the foregoing references are incorporated herein by reference.

Yeast cells are transformed with the DNA molecules of the present invention according to known techniques for introduction of DNA. (See, e.g., Hinnen et al. (1978) PNAS 75:1919-1933 and Stinchcomb et. al. EP 45,523.) Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and typically include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations. Transformation procedures usually vary with the yeast species to be transformed. See, e.g., Kurtz, et al. (1986), Mol. Cell. Biol., 6:142, Kunze, et al. (1985), J. Basic Microbiol., 25:141, for Candida; Gleeson, et al., (1986), J. Gen. Microbiol., 132:3459, Roggenkamp, et al. (1986), Mol. Gen. Genet., 202:302, for Hansenula; Das, et al., (1984), J. Bacteriol., 158:1165, De Louvencourt et al., (1983), J. Bacteriol., 154:1165, Van den Berg, et al., (1990), Bio/Technology, 8:135, for Kluyveromyces; Cregg, et al., (1985), Mol. Cell Biol., 5:3376, Kunze, et al. (1985), J. Basic Microbiol., 25:141, U.S. Patent Nos. 4,837,148 and 4,929,555, for Pichia; Hinnen, et al. (1978), Proc. Natl. Acad. Sci. USA, 75:1929, Ito, et al. (1983), J. Bacteriol., 153:163, for Saccharomyces; Davidow, et al., (1985) Curr. Genet., 10:39, Gaillardin, et al. (1985), Curr. Genet., 10:49, for Yarrowia.

Yeast cells are grown in culture in nutrient media according to well known techniques. (See, e.g., American Type Culture Collection Media Handbook.) According to the present invention yeast cells which "have" a certain DNA molecule contain that molecule stably, that is, the DNA is faithfully replicated in the cells. A single yeast cell, according to the invention can be transformed with DNA for either/or both of the MIP-1 subunits α and β . Thus monomer, homomers and heteromers could be formed in the yeast or in the culture medium.

The practice of the teachings of the present invention leads to compositions containing mammalian MIP-1 proteins. These compositions are substantially free of non-MIP, mammalian proteins, because they are produced in yeast cells. "Substantially free" denotes greater than about 75% by weight MIP relative to the protein content of the entire composition. Preferably, the MIP is greater than about 90% by weight, and most preferably the MIP is greater than about 99% by weight of the protein of the composition. Indeed, compositions in

which the only mammalian protein is an MIP-1 are provided by the present invention.

The following examples are provided for illustrative purposes and do not limit the scope of the invention.

EXAMPLES

Example 1

This example describes the cloning of murine MIP-1 α and murine MIP-1 β coding sequences.

A cDNA library was constructed from Poly(A)⁺ RNA isolated from *E. coli* lipopolysaccharide-stimulated RAW 264.7 (murine macrophage tumor cell line) cells. The cloning of the cDNAs for murine MIP-1 α and murine MIP-1 β are described in Davatelis et al., J. Exp. Med. 167, 1939-1944 (1988), and Sherry et al., J. Exp. Med. 168, 2251-2259 (1988), which are incorporated by reference herein.

Example 2

This example describes the cloning of human MIP-1 α and human MIP-1 β coding sequences.

1. Library Construction

The human monocytic-like cell line U937 was grown to confluence and stimulated to differentiate by the addition of phorbol 12-myristate 13-acetate (PMA) to a final concentration of 5×10^{-8} M. After 24 hours in the presence of PMA, lipopolysaccharide was added to a final concentration of 1 μ g/ml and the cells were incubated for an additional 3 hours at 37°C. Total RNA was prepared essentially as described by Cathala et al., (DNA 2: 329, 1983). Poly A⁺ RNA was prepared by a single passage over oligo-dT cellulose, essentially as described by Okayama et al. (Methods Enzymol. 154, 3, 1987) and Maniatis et al., (Molecular Cloning: A Laboratory manual, Cold Spring Harbor Laboratory, 1982). Double-stranded cDNA was prepared by standard methods and cloned and packaged into λ gt10. Duplicate nitrocellulose filter lifts of the plated library ($5.6-7 \times 10^5$ plaques) were pre-hybridized at 52°C in 50% formamide, 5xSSC, 50mM sodium phosphate buffer, pH6.5, 0.2% SDS, 2x Denhardt's and 0.25 mg/ml sonicated salmon sperm DNA. Filters were then hybridized at 42°C overnight in 50% formamide, 5xSSC, 20mM sodium phosphate, pH6.5,

0.1% SDS, 1xDenhardt's, 10% dextran sulfate, 0.1 mg/ml sonicated salmon sperm DNA and approximately 500,000 cpm per ml of the appropriate ^{32}P -ATP nick-translated murine cDNA probe.

2. Screening for Human Homologs to mu-MIP-1 α , mu-MIP-1 β

In order to screen for human homologs to murine MIP-1 α and MIP-1 β , the following two fragments were isolated. For MIP-1 α , a 236 bp KpnI-SalI fragment was isolated from pMIP200. (Construction of pMIP200 is described below.) This fragment includes all of the murine MIP-1 α mature coding sequence. To screen for homologs to murine MIP-1 β , a 213 bp NcoI-SalI fragment was isolated from pMIP300. (Construction of pMIP300, is described below.) This fragment encodes all but the first two amino acids of the murine MIP-1 β mature coding sequence.

The DNA fragments were nick translated and 500,000 cpm per ml of each nick translated probe was hybridized to the U937 cDNA library. Both probes were included in the first round of screening. Filters were subjected to three low stringency washes for 30 minutes each at room temperature in 2xSSC, 0.1% SDS.

Many positive clones were identified. Nineteen were chosen for a second round of plaque purification. Duplicate filter lifts from these plates were independently hybridized, as described above, with either the murine MIP-1 α or the murine MIP-1 β cDNA probe. Washes were as for the primary screening. This screening showed that under these wash conditions it was not possible to distinguish between clones homologous to murine MIP-1 α and MIP-1 β .

3. Determining the Sequence of Human MIPs

The nucleotide sequence from nine independent phage clones was determined by the dideoxy chain termination method of Sanger et al., (Proc. Natl. Acad. Sci. USA 74, 5463 (1977), following subcloning of insert DNA into the M13 phage vector. Two cDNA homologs were defined. Based on nucleotide sequence homology to the two murine MIP-1 peptides, clones MIP-1 2b, 3a, 4a, 4b and 5b defined the human homolog of mu-MIP-1 α , cDNA hu-MIP-1 α (Figure 1); and clones MIP1-8a, 11b, 13a defined the human homolog to mu-MIP-1 β , cDNA hu-MIP-1 β (Figure 2). Assignment of cDNAs as human homologs of

murine MIP-1 α or -1 β was based on both nucleotide and amino acid homology comparisons. Hu-MIP-1 α has 68.5% (740 nucleotide overlap) homology to mu-MIP-1 α and 57.8% nucleotide homology (555 nt overlap) to mu-MIP-1 β . The percentage nucleotide identity of hu-MIP-1 β to mu-MIP-1 α and mu-MIP-1 β is 59.0% (559 nt overlap) and 72.7% (600 nt overlap) respectively. The percent identity of the predicted protein sequence of hu-MIP-1 α to that of mu-MIP-1 α and mu-MIP-1 β is 75.3% (93 aa overlap) and 58.2% (91 aa overlap) respectively. Similarly hu-MIP-1 β has 59.3% (91 aa overlap) and 74.7% (91 aa overlap) amino acid sequence identity to mu-MIP-1 α and mu-MIP-1 β , respectively. An alignment of the predicted amino acid sequences of these MIP-1 homologs is presented in Figure 3.

Hu-MIP-1 α cDNA is identical to cDNAs LD78 and AT464 isolated previously by Obaru et al., op. cit., and Zipfel et al., op. cit. respectively. Hu-MIP-1 β cDNA is virtually identical to cDNAs isolated by Brown et al., op. cit. Zipfel et al., op. cit., Lipes et al., op. cit. and Miller, et al., op. cit. All of these proteins are members of a newly described family of related proteins which appear to function in the host response to invasion. (See Sherry et al., J. Exp. Med. 168: 2251, 1988, for a review.)

Example 3

This example describes the construction of MIP expression plasmids.

a. pYMIP-200 (murine MIP-1 α)

This plasmid encodes an alpha factor leader linked to the sequence encoding mature murine MIP-1 α . The MIP-1 α mature coding sequence is derived from the corresponding MIP-1 α cDNA (Davatelis et al. (1988) J. Exp. Med. 167 1939-1943). The GAPDH promoter sequence, the alpha factor leader sequence and the alpha factor transcription terminator are derived from plasmid pGAI1, the construction of which is described in European patent application 0 324 274, entitled, "Improved expression and secretion and heterologous proteins in yeast employing truncated alpha-factor leader sequences," the disclosure of which is expressly incorporated by reference herein.

Construction of pYMIP-200 was accomplished as follows. Plasmid pBR322/NAP850 which contains a cDNA encoding MIP-1 α cloned in the EcoR1 site of pBR322 was digested with NdeI and BsmI and the 196 bp fragment encoding all but the first two N-terminal amino acids of the mature MIP-1 α sequence was ligated with the following adaptors:

- a) KpnI-NdeI adaptor
 5' CCTTGGATAAAAAGAGCGCCA 3'
 3' CATGGGAACCTATTTTCTCGCGGTAT 5'
- b) BsmI + Sall adaptor
 5' TGATAGCGTCG 3'
 3' GGACTATCGCAGCAGCT 5'
- ↓
 A (silent mutation, see below)

The resulting fragment was purified on an acrylamide gel. This fragment was then ligated into pGAI1 that had been digested with KpnI and Sall and purified on an agarose gel. Following bacterial transformation and screening, plasmid pMIP200 was obtained. Upon DNA sequencing it was found to have a silent mutation in the nucleotide sequence coding for the C-terminal alanine (GCC→GCT). The BamHI expression cassette from this plasmid was cloned into the BamHI site of shuttle vector pAB24 (see European Patent Application 0 324 274 A1) to generate pYMIP200. pAB24 contains the complete 2 μ sequence (Broach in: Molecular Biology of the Yeast *Saccharomyces*, vol. 1, p. 455 (1981).)

b. pYMIP-300 (murine MIP-1 β)

This plasmid encodes an alpha factor leader linked to the sequence encoding mature murine MIP-1 β . The sequence encoding MIP-1 β is derived from the MIP-1 β cDNA (Sherry et al. (1988) J. Exp. Med. 168, 2251-2259). The GAPDH promoter sequence, the alpha factor leader sequence and the alpha factor transcription terminator are derived from plasmid pGAI1 which is described above. The cDNA encoding MIP-1 β was subjected to in vitro mutagenesis to introduce a restriction endonuclease site which would facilitate the cloning of the MIP-1 β coding region into the expression vector. The mutagenic primer used was:

* * *

- 19 -

3' GTC CCA AGA GGC GGG GGT ACC CGA GAC -5'
 (* refers to nucleotides that are different from those in
 the cDNA sequence)

This primer introduced a NcoI site at the start of the nucleotide sequence encoding the mature MIP-1 β protein. The EcoRI fragment containing the modified MIP-1 β cDNA sequence (containing the NcoI site) was isolated from the M13 phage RF and cloned into the EcoRI site of pBR322 to give plasmid pBR-3-1b/6. This plasmid was cut with BglII and ligated to the following BglII-SalI adaptor which encodes the 20 carboxyl terminal amino acids of MIP-1 β and the stop codon.

IleCysAlaAsnProSerGluProTrpValThrGluTyrMetSerAspLeuGluLeuAsnOP AM ArgArgArg
 GATCTGTGCTAACCCAGTGAGCCCTGGGTCAGTACATGAGCGATCTAGAGCTGAAGTATAGCGCTCG
 ACACGATTGGGGTCACTCGGGACCCAGTGACTCATGTACTCGCTAGATCTCGACTTGACTATCGCAGCAGCT

1 BGL2, 50 XBAI

73 SALI,

Following digestion with NcoI, a 213 bp fragment encoding MIP-1 β and stop codons was purified by acrylamide gel electrophoresis.

The vector pGAI1 was cut with KpnI and ligated with the following KpnI-NcoI adaptor which encodes the 3 carboxyl terminal amino acids of the alpha factor leader, the LysArg processing site and the first two amino acids of mature MIP-1 β .

5' - CCTTGGATAAAAAGAGCCCC -3'
 3' - CATGGGAACCTATTTTCTCGGGGTAC -5'

The vector was then cut with SalI, and the vector fragment purified by agarose gel electrophoresis. The NcoI-SalI vector fragment was ligated with the NcoI-SalI MIP-1 β coding fragment. The ligated product was transformed into *E. coli* and the clone pMIP300/20 was obtained which was found to have the predicted nucleotide sequence. This plasmid was digested with BamHI and the resulting 1155 bp fragment including the GAPDH promoter sequence, the sequence encoding the alpha factor leader-MIP-1 β fusion protein and the alpha factor transcription terminator was cloned into the BamHI site of pAB24 to give the expression plasmid pYMIP300.

c. pYMIP220 (human MIP-1 α)

This plasmid encodes an alpha factor leader linked to the sequence encoding mature hu-MIP-1 α . The hu-MIP-1 α sequence is

derived from the λ gt10 cDNA clone hMIP1-13a. The GAPDH promoter sequence, the alpha factor leader sequence and the alpha factor transcription terminator are derived from plasmid pGAI1, the construction of which is described in European patent application 0324-274. The EcoR1 insert DNA fragment from a λ gt10 clone of human MIP-1 was subjected to 30 cycles of polymerase chain reaction (PCR) with the following primers.

```

5'- primer
5'   GAGTGGGTACCCTTGGATAAAAGAGCATCACTTGCTGCTGACACG
      ↑                               |→hu-MIP-1α
      KpnI

CCGACCGC -3'


3'- primer
5'   GAGTGGTTCGACTCATCAGGCACTCAGCTCCAGGTCGCTGAC   -3'
      ↑   - - | +hu-MIP-1α
      SalI  stop
  
```

The amplified DNA was digested with KpnI and SalI and the 235 bp fragment encoding the 4 carboxyl terminal amino acids of the alpha factor leader, the dibasic processing site, and the entire 70 amino acids of mature hu-MIP-1 α was isolated by acrylamide gel electrophoresis. This fragment was then ligated into pGAI1 that had been digested with KpnI and SalI and purified on an agarose gel. Following bacterial transformation and screening, plasmid pMIP220 was obtained which upon DNA sequencing was found to have the predicted nucleotide sequence. This plasmid was digested with BamHI and the resulting 1154 bp fragment including the GAPDH promoter sequence, the sequence encoding the alpha-factor leader/hu-MIP-1 α fusion protein and the alpha factor transcription terminator was cloned into the BamHI site of pAB24 to give expression plasmid pYMIP220.

d. **pYMIP320**

This plasmid encodes an alpha factor leader linked to the nucleotide sequence encoding mature hu-MIP-1 β . The mature hu-MIP-1 β coding sequence is derived from a λ gt10 cDNA clone of human MIP-1 β . The GAPDH promoter sequence, the alpha factor leader sequence and the alpha factor transcription terminator are

derived from plasmid pGAI1, the construction of which is described in European patent application 0 324 274. The EcoRI insert DNA fragment from the λ gt10 clone containing the hu-MIP-1 β cDNA was subjected to 30 cycles of polymerase chain reaction (PCR) with the following primers.



The amplified DNA was digested with KpnI and Sall and the 232 bp fragment encoding the 4 carboxyl terminal amino acids of the alpha factor leader, the dibasic processing site, the entire 69 amino acids of mature hu-MIP-1 β was isolated by acrylamide gel electrophoresis. This fragment was then ligated into pGAI1 that had been digested with KpnI and Sall and purified on an agarose gel. Following bacterial transformation and screening, plasmid pMIP320 was obtained which upon DNA sequencing was found to have the predicted nucleotide sequence. This plasmid was digested with BamHI and the resulting 1143 bp fragment including the GAPDH promoter sequence, the sequence encoding the alpha factor leader/hu-MIP-1 β fusion protein and the alpha factor transcription terminator was cloned into the BamHI site of pAB24 to give expression plasmid pYMIP320.

Example 4

This example demonstrates the expression of murine MIP-1 α and -1 β and human MIP-1 α and 1- β .

Expression of MIP-1 α

S. cerevisiae strain MB2-1 (leu2-3, leu2-112, his3-11, his3-15 ura3 Δ , pep4 Δ , CAN, cir^o) was transformed with plasmid pYMIP200 or pYMIP220 by standard procedures and transformants selected for uracil prototrophy. Expression was analyzed by inoculation of single colonies

of individual transformants into leucine selective medium and growing at 30°C for ~48 hr. or until the culture is saturated. Cultures were then centrifuged, cells resuspended in medium lacking uracil and diluted 20-fold into uracil selective medium. Cultures were grown for approximately 72 h, then harvested and cell-free supernatants prepared.

Recipes

Leu- Selective Media

50 ml	10X basal salts
25 ml	20X leu- supplements
2 ml	5% threonine
80 ml	50% glucose
5 ml	0.3% of each pantothenic acid and inositol

qs to 500 ml with sterile ddH₂O and then autoclave or sterile filter.

20X supplements

0.5g powdered leu- supplements
per 100 ml of sterile ddH₂O. Autoclave.

Powdered Leu- Supplements

0.8g	Adenine
0.6g	Uridine
0.4g	L-Tryptophan
0.4g	L-Histidine
0.4g	L-Arginine
0.4g	L-Methionine
0.6g	L-Tyrosine
0.6g	L-Lysine
0.96g	L-Phenylalanine

Add all components to a coffee grinder and grind until the powder is homogenous.

Ura- Selective media

500 ml	2% glucose media
50 ml	10X basal salts
20 ml	50% glucose
12.5 ml	20% casamino acids
2.5 ml	1% adenine
2.5 ml	1% tryptophan
5 ml	0.3% of each pantothenic acid and inositol

Conditioned medium was analyzed for the presence of MIP-1 α by SDS-PAGE followed by coomassie staining and, in the case of the murine factor, by immunoblotting. A band was observed on SDS-PAGE of murine MIP-1 α which comigrated with native MIP-1 standard (provided by B. Sherry, Rockefeller University) and showed immunoreactivity with polyclonal antisera raised against murine MIP-1 (antisera provided by B. Sherry). A similar sized stained band was observed upon expression of human MIP-1 α . These proteins were expressed as 1-5% of the secreted protein.

Expression of MIP-1 β

S. cerevisiae strain MB2-1 was transformed with plasmid pYMIP300 or pYMIP320 by standard procedures and transformants selected for uracil prototrophy. Expression studies were performed as described above for MIP-1 α . Similar results were obtained for expression levels.

Thus far, recombinant murine MIP-1 α and MIP-1 β have been shown to have bioactivity of native MIP-1, i.e., CSF-dependent myelopoietic enhancing activity for CFU-GM.

Table of Deposited Cell Lines

<u>Name</u>	<u>Deposit Date</u>	<u>ATCC No.</u>
MB2-1(pYMIP-200)	June 20, 1990	74008
MB2-1(pYMIP-220)	June 20, 1990	74007
MB2-1(pYMIP-300)	June 20, 1990	74006
MB2-1(pYMIP-320)	June 20, 1990	74005

The above materials have been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 under the accession numbers indicated. These deposits will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for purposes of Patent Procedure. These deposits are provided merely as convenience to those of skill in the art, and are not an admission that a deposit is required under 35 U.S.C. Section 112. The sequence of the polynucleotides contained in the deposited materials, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with the

description of sequences herein. A license may be required to make, use or sell the deposited materials, and no such license is hereby granted.

MICROORGANISMS	
Optional Sheet in connection with the microorganism referred to on page <u>17</u> , line <u>24</u> of the description 1	
A. IDENTIFICATION OF DEPOSIT 1	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/> 2	
Name of depository institution 4	
AMERICAN TYPE CULTURE COLLECTION	
Address of depository institution (including postal code and country) 4	
12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit 4	Accession Number 4
June 20, 1990	74008
B. ADDITIONAL INDICATIONS 1 (leave blank if not applicable). This information is continued on a separate attached sheet <input type="checkbox"/>	
MB2-1(pYMIP-200)	
C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE 1 (if the indications are not for all designated States)	
D. SEPARATE FURNISHING OF INDICATIONS 1 (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later 2 (Specify the general nature of the indications e.g., "Accession Number of Deposit")	
E. <input checked="" type="checkbox"/> This sheet was received with the international application when filed (to be checked by the receiving Office)	
<div style="display: flex; align-items: center;"> <div style="border-bottom: 1px solid black; width: 150px; margin-right: 5px;"></div> <div style="margin-right: 5px;">_____</div> <div style="margin-right: 5px;">_____</div> </div>	
(Authorized Officer)	
<input type="checkbox"/> The date of receipt (from the applicant) by the International Bureau 22	
<div style="display: flex; align-items: center;"> <div style="border-bottom: 1px solid black; width: 150px; margin-right: 5px;"></div> <div style="margin-right: 5px;">_____</div> <div style="margin-right: 5px;">_____</div> </div>	
(Authorized Officer)	

International Application No: PCT/

1

MICROORGANISMS	
Optional Sheet in connection with the microorganism referred to on page <u>19</u> , line <u>37</u> of the description *	
A. IDENTIFICATION OF DEPOSIT *	
Further deposits are identified on an additional sheet <input checked="" type="checkbox"/> *	
Name of depository institution *	
AMERICAN TYPE CULTURE COLLECTION	
Address of depository institution (including postal code and country) *	
12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit *	Accession Number *
June 20, 1990	74007
B. ADDITIONAL INDICATIONS * (leave blank if not applicable). This information is continued on a separate attached sheet <input type="checkbox"/>	
MB2-1(pYMIP-220)	
C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE * (if the indications are not for all designated States)	
D. SEPARATE FURNISHING OF INDICATIONS * (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")	
E. <input checked="" type="checkbox"/> This sheet was received with the international application when filed (to be checked by the receiving Office)	
<div style="display: flex; align-items: center; justify-content: center;"> <div style="border-bottom: 1px solid black; width: 150px; margin-right: 5px;"></div> <div style="text-align: center;"> <p><i>Helen Bell</i></p> <p>(Authorized Officer)</p> </div> </div>	
<input type="checkbox"/> The date of receipt (from the applicant) by the International Bureau is:	
<div style="display: flex; align-items: center; justify-content: center;"> <div style="border-bottom: 1px solid black; width: 150px; margin-right: 5px;"></div> <div style="text-align: center;"> <p>(Authorized Officer)</p> </div> </div>	

International Application No: PCT/ 1

MICROORGANISMS

Optional Sheet in connection with the microorganism referred to on page... 18 ... line 27 ... of the description 1

A. IDENTIFICATION OF DEPOSIT 1

Further deposits are identified on an additional sheet 2

Name of depository institution 4

AMERICAN TYPE CULTURE COLLECTION

Address of depository institution (including postal code and country) 4

12301 Parklawn Drive
Rockville, Maryland 20852
United States of America

Date of deposit 6

June 20, 1990

Accession Number 6

74006

B. ADDITIONAL INDICATIONS 1 (leave blank if not applicable). This information is continued on a separate attached sheet

MB2-1(pYMIP-300)

C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE 1 (if the indications are not for all designated States)

D. SEPARATE FURNISHING OF INDICATIONS 1 (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later 1 (Specify the general nature of the indications 10, - Accession Number of Deposit 7)

E. This sheet was received with the international application when filed (to be checked by the receiving Office)

Helen Hill

(Authorized Officer)

The date of receipt (from the applicant) by the International Bureau 10

was

(Authorized Officer)

International Application No: PCT/ /

MICROORGANISMS	
Optional Sheet in connection with the microorganism referred to on page <u>20</u> , line <u>35</u> of the description *	
A. IDENTIFICATION OF DEPOSIT *	
Further deposits are identified on an additional sheet <input type="checkbox"/> *	
Name of depository institution *	
AMERICAN TYPE CULTURE COLLECTION	
Address of depository institution (including postal code and country) *	
12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit *	Accession Number *
June 20, 1990	74005
B. ADDITIONAL INDICATIONS * (leave blank if not applicable). This information is continued on a separate attached sheet <input type="checkbox"/>	
MB2-1(pYMIP-320)	
C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE * (if the indications are not for all designated States)	
D. SEPARATE FURNISHING OF INDICATIONS * (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later * (Specify the general nature of the indications e.g., "Accession Number of Deposit")	
E. <input checked="" type="checkbox"/> This sheet was received with the international application when filed (to be checked by the receiving Office)	
<div style="display: flex; align-items: center; justify-content: center;"> <div style="border-bottom: 1px solid black; width: 150px; margin-right: 5px;"></div> <div style="text-align: center;"> <p><i>Helen Bell</i></p> <p>(Authorized Officer)</p> </div> </div>	
<input type="checkbox"/> The date of receipt (from the applicant) by the International Bureau is *	
<div style="display: flex; align-items: center; justify-content: center;"> <div style="border-bottom: 1px solid black; width: 150px; margin-right: 5px;"></div> <div style="text-align: center;"> <p>(Authorized Officer)</p> </div> </div>	

CLAIMS

1. A DNA molecule comprising in order of transcription:
 - (a) a transcription regulatory region operative in a yeast;
 - (b) a region which encodes a mammalian protein selected from the group consisting of MIP-1 α , and MIP-1 β .
2. The DNA molecule of claim 1 wherein region (a) provides inducible transcriptional regulation.
3. The DNA molecule of claim 1 wherein region (a) provides constitutive transcriptional regulation.
4. The DNA molecule of claim 1 further comprising:
a leader fragment which facilitates secretion of the mammalian protein, said fragment covalently linked to region (b).
5. The DNA molecule of claim 4 wherein the leader fragment encodes a yeast alpha-factor leader.
6. The DNA molecule of claim 4 wherein the leader fragment encodes a truncated yeast alpha-factor leader.
7. The DNA molecule of claim 1 further comprising:
 - (c) a terminator region operative in a yeast.
8. The DNA molecule of claim 1 wherein region (c) is derived from a yeast alpha-factor transcription terminator.
9. The DNA molecule of claim 1 wherein region (b) has been mutagenized to introduce a restriction enzyme recognition site.
10. The DNA molecule of claim 1 further comprising:
 - (d) a replication system operative in a yeast.
11. A yeast cell comprising a DNA molecule according to claim 1.
12. A yeast cell comprising a DNA molecule according to claim 10.
13. A yeast cell comprising a DNA molecule according to claim 4.
14. A method for producing a MIP polypeptide which comprises:

growing a yeast cell according to claim 11 in a nutrient medium whereby region (b) is expressed to produce a MIP.

15. A method for producing a MIP polypeptide which comprises:

growing a yeast cell according to claim 12 in a nutrient medium whereby region (b) is expressed to produce a MIP.

16. A method for producing a MIP polypeptide which comprises:

growing a yeast cell according to claim 13 in a nutrient medium whereby region (b) is expressed and secreted to produce a MIP.

17. The method of claim 16 wherein the leader fragment comprises a yeast alpha-factor leader and processing signal.

18. The method of claim 16 wherein the leader fragment comprises a truncated yeast alpha-factor leader.

19. A composition comprising a mammalian MIP protein selected from the group consisting of murine MIP-1 α , murine MIP-1 β , human MIP-1 α , and human MIP-1 β wherein the MIP is substantially free of non-MIP, mammalian proteins.

20. The composition of claim 19 wherein the MIP is human MIP-1 α , and the composition further comprises human MIP-1 β .

21. The composition of claim 19 comprising murine MIP-1 α and murine MIP-1 β .

Human MIP-1α cDNA

```

                                -22     -20
                                Met Gln Val Ser Thr Ala Ala Leu
CCACATTCCGTCACCTGCTCAGAATC ATG CAG GTC TCC ACT GCT GCC CTT

                                -10
Ala Val Leu Leu Cys Thr Met Ala Leu Cys Asn Gln Phe Ser Ala
GCT GTC CTC CTC TGC ACC ATG GCT CTC TGC AAC CAG TTC TCT GCA
                                                                1

                                10
Ser Leu Ala Ala Asp Thr Pro Thr Ala Cys Cys Phe Ser Tyr Thr
TCA CTT GCT GCT GAC ACG CCG ACC GCC TGC TGC TTC AGC TAC ACC

                                20
Ser Arg Gln Ile Pro Gln Asn Phe Ile Ala Asp Tyr Phe Glu Thr
TCC CGG CAG ATT CCA CAG AAT TTC ATA GCT GAC TAC TTT GAG ACG

                                30

Ser Ser Gln Cys Ser Lys Pro Gly Val Ile Phe Leu Thr Lys Arg
AGC AGC CAG TGC TCC AAG CCC GGT GTC ATC TTC CTA ACC AAG CGA

                                40

Ser Arg Gln Val Cys Ala Asp Pro Ser Glu Glu Trp Val Gln Lys
AGC CGG CAG GTC TGT GCT GAC CCC AGT GAG GAG TGG GTC CAG AAA

                                50
                                60

Tyr Val Ser Asp Leu Glu Leu Ser Ala OP
TAT GTC AGC GAC CTG GAG CTG AGT GCC TGA GGGGTCCAGAAGCTTCCGAGG
.

CCCAGCGACCTCGGTGGGCCAGTGGGGAGGAGCAGGAGCCTGAGCCTTGGGAACATGCGT
.
                                +100
GTGACCTCCACAGCTACCTCTTCTATGGACTGGTTGTTGCCAAACAGCCACACTGTGGGA
.
                                +200
CTCTTCTTAACTTAAATTTAATTTATTACTATTTAGTTTTTGTAAATTTATTTTGA
.

TTTCACAGTGTGTTTGTGATGTTTGCTCTGAGAGTCCCCTGTCCCCTCCCCCTTCCCT
.
                                +300
CACACCGCGTCTGGTGACAACCGAGTGGCTGTCATCAGCCTGTGTAGGCAGTCATGGCAC
.

CAAAGCCACCAGACTGACAAATGTGTATCGGATGCTTTTGTTCAGGGCTGTGATCGGCCCT
.
                                +400
GGGGAAATAATAAAGATGCTCTTTTAAAA
    
```

Figure 2

Human-MIP-1 β

```

                .           .           .
                -23           -20
                Met Lys Leu Cys Val
AGCCTCACCTCTGAGAAAACCTCTTTTCCACCAATACC ATG AAG CTC TGC GTG

                -10
Thr Val Leu Ser Leu Leu Met Leu Val Ala Ala Phe Cys Ser Pro
ACT GTC CTG TCT CTC CTC ATG CTA GTA GCT GCC TTC TGC TCT CCA

                1           10
Ala Leu Ser Ala Pro Met Gly Ser Asp Pro Pro Thr Ala Cys Cys
GCG CTC TCA GCA CCA ATG GGC TCA GAC CCT CCC ACC GCC TGC TGC

                20
Phe Ser Tyr Thr Ala Arg Lys Leu Pro Arg Asn Phe Val Val Asp
TTT TCT TAC ACC GCG AGG AAG CTT CCT CGC AAC TTT GTG GTA GAT

                30           40
Tyr Tyr Glu Thr Ser Ser Leu Cys Ser Gln Pro Ala Val Val Phe
TAC TAT GAG ACC AGC AGC CTC TGC TCC CAG CCA GCT GTG GTA TTC

                50
Gln Thr Lys Arg Ser Lys Gln Val Cys Ala Asp Pro Ser Glu Ser
CAA ACC AAA AGA AGC AAG CAA GTC TGT GCT GAT CCC AGT GAA TCC

                60           69
Trp Val Gln Glu Tyr Val Tyr Asp Leu Glu Leu Asn OP
TGG GTC CAG GAG TAC GTG TAT GAC CTG GAA CTG AAC TGA GCTGCTCA
.
.
.
GAGACAGGAAGTCTTCAGGGAAGGTCACCTGAGCCCGGATGCTTCTCCATGAGACACATC
.
.
.
TCCTCCATACTCAGGACTCCTCTCCGCAGTTCCTGTCCCTTCTCTTAATTTAATCTTTTT
.
.
.
TATGTGCCGTGTTATTGTATTAGGTGTCATTCCATTATTTATATTAGTTTAGCCAAAGG
.
.
.
ATAAGTGTCTATGGGGATGGTCCACTGTCACTGTTTCTCTGCTGTTGCAAATACATGGA
.
.
.
TAACACATTTGATTCTG
    
```

AMINO ACID ALIGNMENT OF MIP-1 HOMOLOGS

```

1. hu-MIP-1α  1 MqVSTaALAVLLCTMaLCNO FSAaIaADTPTACCFStSRqIPqnFIaDYFETSSqCSkPGVIFLTKRαRQ
  ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
2. mu-MIP-1α  1 MKVSTtALAVLLCTMtLCNOvFSAPyGADTPTACCFStSRkIPRqFivDYFETSSLCSqPGVIFLTKRαRQ
  ||  || || || | ||||| || ||||| || || || ||||| || ||||| || ||||| || ||||| || ||||| ||
3. mu-MIP-1β  1 MKLCVsALSLLLVAAPCaPgFSAPMGSDPPTsCCFSYTSRqLhRsFvMDYYETSSLCSkPAVVFLTKRgRQ
  ||||| ||||| ||||| | ||||| || ||||| || ||||| || ||||| || ||||| || ||||| ||||| ||| |
4. hu-MIP-1β  1 MKLCVtLsLLmLVAAPCsPalsAPMGSDPPTaCCFSYTaRkLpRnFvDYYETSSLCSqPAVVfQTKRskQ

1. hu-MIP-1α  72 vCADpsEeWVQkYvsDLELsA
  ||| | ||| | |||| |
2. mu-MIP-1α  72 ICADskEtWVQEYItDLELNA
  ||| | || || |||||
3. mu-MIP-1β  73 ICAnPSEpWVtEYmsDLELN
  || ||| || || |||||
4. hu-MIP-1β  73 vCADpSEsWVqEYvyDLELN

```

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 91/06489

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶				
According to International Patent Classification (IPC) or to both National Classification and IPC				
Int.Cl. 5 C07K15/00;	C12N1/19;	C12P21/02; C12N15/62		
II. FIELDS SEARCHED				
Minimum Documentation Searched ⁷				
Classification System	Classification Symbols			
Int.Cl. 5	C07K ; C12N			
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸				
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹				
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³		
X	WO,A,9 007 009 (THE UNITED STATES OF AMERICA) 28 June-1990 see the whole document ---	1-19		
X	MOLECULAR AND CELLULAR BIOLOGY vol. 10, no. 7, July 1990, WASHINGTON, D.C. U.S.A. pages 3646 - 3658; M. NAKAO ET AL.: 'Structures of human genes coding for cytokine LD78 and their expression' "Introduction" see figure 3 --- -/-	1-19		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> ¹⁰ Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none; vertical-align: top;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "Δ" document member of the same patent family </td> </tr> </table>			¹⁰ Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "Δ" document member of the same patent family
¹⁰ Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "Δ" document member of the same patent family			
IV. CERTIFICATION				
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report			
18 DECEMBER 1991	08 JAN 1992'			
International Searching Authority	Signature of Authorized Officer			
EUROPEAN PATENT OFFICE	VAN PUTTEN A. J.			

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		Relevant to Claim No.
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	
X	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 86, March 1989, WASHINGTON US pages 1963 - 1967; B.S. KWON AND S.M. WEISSMAN: 'cDNA sequences of 2 inducible T-cell genes' cited in the application see figure 1</p>	19
X	<p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 85, December 1988, WASHINGTON US pages 9704 - 9708; M.A. LIPES ET AL.: 'Identification, cloning, and characterization of an immune activation gene' cited in the application see figure 3</p>	1-19
X	<p>JOURNAL OF IMMUNOLOGY. vol. 142, no. 2, 15 January 1989, BALTIMORE US pages 679 - 687; K.D. BROWN ET AL.: 'A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast -derived inflammatory agents, growth factors, and indicators of various activation processes' cited in the application "materials and methods"</p>	19
X	<p>EP,A,0 310 136 (THE ROCKEFELLER UNIVERSITY) 5 April 1989 see page 5, line 15 - page 5, line 16</p>	20,21
P,X	<p>WO,A,9 104 274 (GENETICS INSTITUTE, INC.; CRC TECHNOLOGY LTD.) 4 April 1991 see page 36, line 15 - page 36, line 25</p>	1,11,14
A	<p>EP,A,0 324 274 (CHIRON CORPORATION) 19 July 1989 cited in the application see the whole document</p>	1-18

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. US 9106489
SA 51409**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 18/12/91

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9007009	28-06-90	AU-A- 4816090	10-07-90
		CA-A- 2005639	16-06-90
		EP-A- 0449956	09-10-91
		JP-T- 3504331	26-09-91
EP-A-0310136	05-04-89	AU-A- 2333688	27-07-89
WO-A-9104274	04-04-91	None	
EP-A-0324274	19-07-89	AU-A- 2765088	06-07-89
		JP-A- 2002339	08-01-90

EPO FORM P0079

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT OR DRAWING
- BLURRED OR ILLEGIBLE TEXT OR DRAWING
- SKEWED/SLANTED IMAGES
- COLOR OR BLACK AND WHITE PHOTOGRAPHS
- GRAY SCALE DOCUMENTS
- LINES OR MARKS ON ORIGINAL DOCUMENT
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.